Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I, Valcárcel D, Martino R, Piñana JL, Novelli S, Esquirol A, Garrido A, Moreno ME, Granell M, Moreno C, Saavedra S, Briones J, Brunet S, Sierra J. García-Cadenas I, et al. Among authors: moreno me, moreno c. Biol Blood Marrow Transplant. 2013 Mar;19(3):435-9. doi: 10.1016/j.bbmt.2012.11.012. Epub 2012 Nov 20. Biol Blood Marrow Transplant. 2013. PMID: 23178634 Free article.
How I treat refractory CLL.
Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F. Montserrat E, et al. Among authors: moreno c. Blood. 2006 Feb 15;107(4):1276-83. doi: 10.1182/blood-2005-02-0819. Epub 2005 Oct 4. Blood. 2006. PMID: 16204307 Free article. Review.
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S, Moreno C, Domingo-Doménech E, Estany C, Oriol A, Altés A, Besalduch J, Pedro C, Gardella S, Escoda L, Asensio A, Vivancos P, Galán P, de Sevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) Spain. Montoto S, et al. Among authors: moreno c. Haematologica. 2008 Feb;93(2):207-14. doi: 10.3324/haematol.11671. Epub 2008 Jan 26. Haematologica. 2008. PMID: 18223288 Free article. Clinical Trial.
Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.
García Cadenas I, Valcarcel D, Martino R, Piñana JL, Barba P, Novelli S, Esquirol A, Garrido A, Saavedra S, Granell M, Moreno C, Briones J, Brunet S, Sierra J. García Cadenas I, et al. Among authors: moreno c. Mediators Inflamm. 2014;2014:620682. doi: 10.1155/2014/620682. Epub 2014 Jan 30. Mediators Inflamm. 2014. PMID: 24623962 Free PMC article.
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Dreger P, et al. Among authors: moreno c. Blood. 2014 Dec 18;124(26):3841-9. doi: 10.1182/blood-2014-07-586826. Epub 2014 Oct 9. Blood. 2014. PMID: 25301705 Free PMC article. Review.
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.
García-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C, Granell M, Briones J, Brunet S, Navarro F, Ruiz I, Rabella N, Valcárcel D, Sierra J. García-Cadenas I, et al. Among authors: moreno c. Bone Marrow Transplant. 2015 Apr;50(4):579-84. doi: 10.1038/bmt.2014.298. Epub 2015 Jan 12. Bone Marrow Transplant. 2015. PMID: 25581404
The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).
Montesinos P, Cabrero M, Valcárcel D, Rovira M, García-Marco JA, Loscertales J, Moreno C, Duarte R, Terol MJ, Villamor N, Abrisqueta P, Caballero D, Sanz J, Delgado J. Montesinos P, et al. Among authors: moreno c. Bone Marrow Transplant. 2016 Oct;51(10):1404-1407. doi: 10.1038/bmt.2016.145. Epub 2016 May 23. Bone Marrow Transplant. 2016. PMID: 27214073 Clinical Trial. No abstract available.
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Kharfan-Dabaja MA, et al. Among authors: moreno c. Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Biol Blood Marrow Transplant. 2016. PMID: 27660167 Free PMC article. Review.
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.
Magnano L, Montoto S, González-Barca E, Briones J, Sancho JM, Muntañola A, Salar A, Besalduch J, Escoda L, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altés A, Pedro C, Gardella S, Asensio A, Vivancos P, Fernández de Sevilla A, Ribera JM, Colomer D, Campo E, López-Guillermo A. Magnano L, et al. Among authors: moreno c. Ann Hematol. 2017 Apr;96(4):639-646. doi: 10.1007/s00277-017-2920-2. Epub 2017 Jan 18. Ann Hematol. 2017. PMID: 28101592 Clinical Trial.
2,001 results